Trial Profile

A randomized, double-blind, placebo-controlled, phase II clinical trial to evaluate the safety, pharmacokinetics and efficacy of TNP-2092 Capsule in patients diagnosed with liver cirrhosis with hyperammonemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaquizinone (Primary)
Indications Hepatic encephalopathy
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors TenNor Therapeutics

07 Dec 2021 New trial record
22 Nov 2021 According to a TenNor Therapeutics media release, Prof. Junqi Niu, Director and Chief Physician of the Department of Liver Diseases at the First Hospital of Jilin University, is a the co-Principal Investigator of the study.
22 Nov 2021 Results presented in a TenNor Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com